When did Nurix Therapeutics, Inc. report Q2 2025 earnings?

Nurix Therapeutics, Inc. (NRIX) reported Q2 2025 earnings on July 9, 2025 before market open.

What were Nurix Therapeutics, Inc.'s Q2 2025 revenue and EPS?

Nurix Therapeutics, Inc. reported revenue of $44.1M and diluted EPS of $-0.52 for Q2 2025.

Revenue beat the consensus estimate of $17.5M by $26.5M. EPS beat the consensus estimate of $-0.71 by $0.19.

Compared to the same quarter a year prior, revenue grew 264.3% from $12.1M a year earlier and diluted EPS grew 26.8% from $-0.71.

You can read the 10-Q periodic report (0001549595-25-000095) directly on SEC EDGAR. The filing index links above go to sec.gov.

Reported July 9, 2025 · Before market open

Revenue estimate$17.5M

EPS estimate-$0.71

Jul 9, 2026 (In 2 weeks)

Revenue estimate$15.3M

EPS estimate-$0.73

Q2 2025$44.1MBeat by $26.5M

Q2 2025-$0.52Beat by $0.19

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

When did Nurix Therapeutics, Inc. report Q2 2025 earnings?: Nurix Therapeutics, Inc. (NRIX) reported Q2 2025 earnings on July 9, 2025 before market open.
What were Nurix Therapeutics, Inc.'s Q2 2025 revenue and EPS?: Nurix Therapeutics, Inc. reported revenue of $44.1M and diluted EPS of $-0.52 for Q2 2025.
Did Nurix Therapeutics, Inc. beat estimates in Q2 2025?: Revenue beat the consensus estimate of $17.5M by $26.5M. EPS beat the consensus estimate of $-0.71 by $0.19.
How did Nurix Therapeutics, Inc.'s Q2 2025 results compare year-over-year?: Compared to the same quarter a year prior, revenue grew 264.3% from $12.1M a year earlier and diluted EPS grew 26.8% from $-0.71.
Where can I find Nurix Therapeutics, Inc.'s Q2 2025 SEC filings?: You can read the 10-Q periodic report (0001549595-25-000095) directly on SEC EDGAR. The filing index links above go to sec.gov.